Hangzhou Tigermed Consulting Co., Ltd. (300347.SZ)
CNY 44.64
(-1.28%)
CNY 44.64
(-1.28%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 5.22 Billion CNY | 9.73% |
| 2022 | 4.76 Billion CNY | 51.96% |
| 2021 | 3.13 Billion CNY | 90.34% |
| 2020 | 1.64 Billion CNY | -18.07% |
| 2019 | 2.01 Billion CNY | 61.44% |
| 2018 | 1.24 Billion CNY | 63.0% |
| 2017 | 764.17 Million CNY | 39.31% |
| 2016 | 548.54 Million CNY | 0.81% |
| 2015 | 544.11 Million CNY | 23.46% |
| 2014 | 440.72 Million CNY | 733.66% |
| 2013 | 52.86 Million CNY | 37.24% |
| 2012 | 38.51 Million CNY | -5.43% |
| 2011 | 40.73 Million CNY | 68.85% |
| 2010 | 24.12 Million CNY | 4.29% |
| 2009 | 23.13 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 5.53 Billion CNY | 5.88% |
| 2024 Q2 | 6.36 Billion CNY | 14.88% |
| 2024 Q3 | 5.85 Billion CNY | -7.91% |
| 2023 Q2 | 5.7 Billion CNY | 17.62% |
| 2023 Q4 | 5.22 Billion CNY | -5.29% |
| 2023 FY | 5.22 Billion CNY | 9.73% |
| 2023 Q3 | 5.52 Billion CNY | -3.29% |
| 2023 Q1 | 4.85 Billion CNY | 1.85% |
| 2022 Q3 | 4.94 Billion CNY | 17.58% |
| 2022 Q2 | 4.2 Billion CNY | 15.88% |
| 2022 Q4 | 4.76 Billion CNY | -3.65% |
| 2022 Q1 | 3.62 Billion CNY | 15.75% |
| 2022 FY | 4.76 Billion CNY | 51.96% |
| 2021 Q3 | 2.35 Billion CNY | 19.28% |
| 2021 FY | 3.13 Billion CNY | 90.34% |
| 2021 Q2 | 1.97 Billion CNY | 11.44% |
| 2021 Q4 | 3.13 Billion CNY | 33.19% |
| 2021 Q1 | 1.77 Billion CNY | 7.5% |
| 2020 Q1 | 2.38 Billion CNY | 18.45% |
| 2020 Q3 | 1.3 Billion CNY | -50.33% |
| 2020 FY | 1.64 Billion CNY | -18.07% |
| 2020 Q4 | 1.64 Billion CNY | 26.41% |
| 2020 Q2 | 2.62 Billion CNY | 10.16% |
| 2019 Q2 | 1.65 Billion CNY | 28.82% |
| 2019 Q4 | 2.01 Billion CNY | 53.41% |
| 2019 FY | 2.01 Billion CNY | 61.44% |
| 2019 Q1 | 1.28 Billion CNY | 3.38% |
| 2019 Q3 | 1.31 Billion CNY | -20.98% |
| 2018 Q4 | 1.24 Billion CNY | 32.75% |
| 2018 FY | 1.24 Billion CNY | 63.0% |
| 2018 Q3 | 938.32 Million CNY | 1.5% |
| 2018 Q2 | 924.46 Million CNY | -4.52% |
| 2018 Q1 | 968.23 Million CNY | 26.7% |
| 2017 FY | 764.17 Million CNY | 39.31% |
| 2017 Q1 | 506.56 Million CNY | -7.65% |
| 2017 Q2 | 604.13 Million CNY | 19.26% |
| 2017 Q4 | 764.17 Million CNY | 6.37% |
| 2017 Q3 | 718.43 Million CNY | 18.92% |
| 2016 Q4 | 548.54 Million CNY | 3.9% |
| 2016 Q3 | 527.93 Million CNY | -6.08% |
| 2016 Q2 | 562.08 Million CNY | 11.57% |
| 2016 FY | 548.54 Million CNY | 0.81% |
| 2016 Q1 | 503.79 Million CNY | -7.41% |
| 2015 Q2 | 197.18 Million CNY | -10.64% |
| 2015 Q3 | 400.41 Million CNY | 103.07% |
| 2015 Q4 | 544.11 Million CNY | 35.89% |
| 2015 Q1 | 220.65 Million CNY | -49.93% |
| 2015 FY | 544.11 Million CNY | 23.46% |
| 2014 Q1 | 97.67 Million CNY | 84.77% |
| 2014 Q4 | 440.72 Million CNY | 18.39% |
| 2014 Q3 | 372.27 Million CNY | 254.28% |
| 2014 Q2 | 105.07 Million CNY | 7.57% |
| 2014 FY | 440.72 Million CNY | 733.66% |
| 2013 Q1 | 35.41 Million CNY | -8.05% |
| 2013 FY | 52.86 Million CNY | 37.24% |
| 2013 Q4 | 52.86 Million CNY | 66.92% |
| 2013 Q3 | 31.67 Million CNY | -3.16% |
| 2013 Q2 | 32.7 Million CNY | -7.67% |
| 2012 Q4 | 38.51 Million CNY | 8.14% |
| 2012 FY | 38.51 Million CNY | -5.43% |
| 2012 Q2 | 36.3 Million CNY | 0.0% |
| 2012 Q3 | 35.62 Million CNY | -1.88% |
| 2011 Q4 | 40.73 Million CNY | 0.0% |
| 2011 FY | 40.73 Million CNY | 68.85% |
| 2010 FY | 24.12 Million CNY | 4.29% |
| 2009 FY | 23.13 Million CNY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 8.02 Billion CNY | 34.83% |
| Dirui Industrial Co.,Ltd. | 1.26 Billion CNY | -314.174% |
| Beijing Strong Biotechnologies, Inc. | 1.45 Billion CNY | -259.606% |
| Medicalsystem Biotechnology Co., Ltd. | 772.59 Million CNY | -576.861% |
| Maccura Biotechnology Co.Ltd | 1.5 Billion CNY | -246.826% |
| Guangzhou Wondfo Biotech Co.,Ltd | 1.15 Billion CNY | -351.942% |
| Guangdong Hybribio Biotech Co.,Ltd. | 615.23 Million CNY | -749.983% |
| BGI Genomics Co., Ltd. | 3.6 Billion CNY | -44.899% |
| Amoy Diagnostics Co., Ltd. | 221.04 Million CNY | -2265.773% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | 1 Billion CNY | -419.461% |